Get a 20% discount to my favorite book summary service at shortform.com/artemSocials: X/Twitter: https://twitter.com/ArtemKRSVPatreon: https://patreon.com/artemki…
Category: neuroscience – Page 9
Can our thoughts, our very essence of being, be explained by the enigmatic laws governing the subatomic world? The Quantum Mind theory proposes just that — a radical idea suggesting that consciousness isn’t just a product of neurons firing, but intricately woven into the fabric of quantum physics. This isn’t the plot of a science fiction novel, but a burgeoning field of study captivating scientists and philosophers alike.
While seemingly disparate, the realms of quantum physics and human consciousness share a curious connection. Quantum mechanics, the study of the universe’s tiniest constituents, reveals a reality vastly different from our everyday experience, a world of probabilities and interconnectedness. Could this be the missing piece in understanding our own inner world, the subjective experience of being conscious?
This essay explores the fascinating intersection of these two fields, examining how the peculiar characteristics of the quantum realm might hold the key to unlocking the secrets of consciousness.
01:06 How much is a Tesla Cybercab?
11:22 How have the features and upgrades of the Tesla Cybercab been enhanced?
===
What do you think of a car that can drive itself from the factory straight to your home? A car that will automatically head to the police station if someone tries to steal it or take you to the hospital if you lose consciousness while driving. Or simply, it allows you to enjoy a deep, restful sleep after work and wake up right at your doorstep.
Recently, Elon Musk and his team confidently announced that this vehicle would be available to consumers at just one-fifth the ticket price of Waymo, an incredible deal for two passengers! And you can rest assured about safety, as it has been verified to be 8.5 times safer than a traditional human-driven car.
In today’s episode, we’ll compile all the latest updates on its performance, impressive specifications, final pricing, and a detailed breakdown of its production process, all packed into this 19 minutes. Welcome to Tesla Car World!
As Tesla said the new Cybercab could cost Tesla only half as much to manufacture as a Model Y. This means ticket prices could be significantly lower compared to Waymo, which charges nearly five times the price of a Robotaxi and incurs much higher operating costs due to extensive mapping requirements. This presents a massive profit opportunity for Tesla while offering an incredibly affordable fare for up to two passengers!
Moreover, for the price of a bus ticket—which isn’t always the most pleasant experience—you get a private space, your own cabin. You can relax, sleep, work, entertain yourself, watch a great movie, and travel in the most comfortable and efficient way possible aboard Tesla’s Cybercab.
===
#888999evs #teslacarworld #teslacar #888999 #teslarobotaxi #cybercab #teslacybercab.
subcribe: https://bit.ly/3i7gILj
A study has found that the cortex acts like a ‘memory machine’, encoding new experiences and predicting the near future, helping to differentiate between novel and old information.
A recent study in an animal model provides direct evidence for the role of the vagus nerve in gut microbiome-brain communication, addressing a critical gap in the field.
The research—led by Kelly G. Jameson, as a Ph.D. student in the Hsiao Lab at UCLA—demonstrates a clear causal relationship between gut microbiota and vagal nerve activity. The work is published in the journal iScience.
While the vagus nerve has long been thought to facilitate communication between the gut microbiome—the community of microorganisms living in the intestines—and the brain, direct evidence for this process has been limited. Researchers led by Jameson observed that mice raised without any gut bacteria, known as germ-free mice, exhibited significantly lower activity in their vagus nerve compared to mice with a normal gut microbiome. Notably, when these germ-free mice were introduced to gut bacteria from normal mice, their vagal nerve activity increased to normal levels.
Using the latest brain preservation techniques, could we ever abolish death? And if so, should we?
Watch the Q&A here (exclusively for our Science Supporters): https://youtu.be/iSIIDJS2a2U
Buy Ariel’s book here: https://geni.us/xvi1Ivf.
This lecture was recorded at the Ri on 2 December 2024.
Just as surgeons once believed pain was good for their patients, some argue today that death brings meaning to life. But given humans rarely live beyond a century – even while certain whales can thrive for over two hundred years – it’s hard not to see our biological limits as profoundly unfair.
I presented these slides (PDF and images below) during the Workshop on Philosophy and Ethics of Brain Emulation (January 28th-29th, 2025) at the Mimir Center for Long Term Futures Research in Stockholm, Sweden. In my talk, I explored how various biological phenomena beyond standard neuronal electrophysiology may exert noticeable effects on the computations underlying subjective experiences. I emphasized the importance of the large range of timescales that such phenomena operate over (milliseconds to years). If we are to create emulations which think and feel like human beings, we must carefully consider the numerous tunable regulatory mechanisms the brain uses to enhance the complexity of its computational repertoire.
While the trial is limited to members of families with genetic mutations that all but guarantee they will develop Alzheimer’s at a young age, typically in their 30s, 40s or 50s, the researchers expect that the study’s results will inform prevention and treatment efforts for all forms of Alzheimer’s disease.
Called the Primary Prevention Trial, the new study investigates whether remternetug — an investigational antibody being developed by Eli Lilly and Company — can remove plaques of a key Alzheimer’s protein called amyloid beta from the brain or block them from accumulating in the first place. Both genetic and nongenetic forms of Alzheimer’s disease start with amyloid slowly collecting in the brain two decades before memory and thinking problems arise. By clearing out low levels of amyloid beta plaques or preventing them from accumulating during the early, asymptomatic phase of the disease, or both, the researchers hope to interrupt the disease process at the earliest stage and spare people from ever developing symptoms.
“We have seen tremendous progress in the treatment of Alzheimer disease in the past few years,” said Eric McDade, DO, a professor of neurology and the trial’s principal investigator. “Two amyloid-targeting drugs were shown to slow symptoms of the disease and have now been approved by the Food and Drug Administration (FDA) as treatments for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. This provides strong support for our hypothesis that intervening when amyloid beta plaques are at the very earliest stage, long before symptoms arise, could prevent symptoms from emerging in the first place.”
The trial is part of the Knight Family Dominantly Inherited Alzheimer Network-Trials Unit (Knight Family DIAN-TU), a clinical trials platform designed to find medicines to prevent or treat Alzheimer’s disease. It is closely associated with DIAN, a National Institutes of Health (NIH)-funded international research network led by WashU Medicine that involves research institutes in North America, Australia, Europe, Asia and South America. DIAN follows families with mutations in any of three genes that cause Alzheimer’s at a young age. A child born into such a family has a 50% chance of inheriting such a mutation, and those who do so typically develop signs of dementia near the same age his or her parent did. All the participants in the Primary Prevention Trial come from such families.
“My grandfather passed away from Alzheimer’s, and so did his mother and all but one of his brothers,” said Hannah Richardson, 24, a participant in the Primary Prevention Trial. “My mom and my uncle have been participating in DIAN trials since I was about 10 years old. My mom was always very open about her diagnosis and how it spurred her advocacy for Alzheimer’s research, and I’ve always known I wanted to follow in her footsteps. I am happy to be involved in the Primary Prevention Trial and be involved in research because I know how important it is.”
This review discusses the links between the autophagy pathway, aging, and age-associated neurodegeneration in Alzheimer’s, Parkinson’s, motor neuron, and Huntington’s diseases. The authors highlight the functions of autophagy in neurons and glia and how aging and neurodegenerative diseases affect autophagy.
UC Davis Health is pleased to announce that Neurosurgeon David Brandman and his team at UC Davis Neuroprosthetics Lab were selected for a 2025 Top Ten Clinical Research Achievement Award. The Clinical Research Forum presents this award to honor 10 outstanding clinical research studies published in peer-reviewed journals in the previous year. This year’s Top 10 Awards ceremony will be held on April 14 in Washington, D.C.
Brandman and his team are recognized for their groundbreaking work in developing a new brain-computer interface (BCI) that translates brain signals into speech with up to 97% accuracy — the most accurate system of its kind. Their work was published in the New England Journal of Medicine.
“Our team is very honored that our study was selected among the nation’s best published clinical research studies. Our work demonstrates the most accurate speech neuroprosthesis (device) ever reported,” said Brandman, co-director of the Neuroprosthetics Lab. He is an assistant professor in the UC Davis Department of Neurological Surgery.